- Home
- AEON vs KZIA Comparison
AEON vs KZIA Comparison
Compare AEON & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AEON
- KZIA
- Stock Information
- Founded
- AEON N/A
- KZIA 1994
- Country
- AEON United States
- KZIA Australia
- Employees
- AEON N/A
- KZIA N/A
- Industry
- AEON Biotechnology: Pharmaceutical Preparations
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- AEON Health Care
- KZIA Health Care
- Exchange
- AEON Nasdaq
- KZIA Nasdaq
- Market Cap
- AEON 10.6M
- KZIA 11.7M
- IPO Year
- AEON N/A
- KZIA 1999
- Fundamental
- Price
- AEON $0.89
- KZIA $7.56
- Analyst Decision
- AEON Strong Buy
- KZIA Strong Buy
- Analyst Count
- AEON 1
- KZIA 3
- Target Price
- AEON $7.20
- KZIA $16.00
- AVG Volume (30 Days)
- AEON 258.2K
- KZIA 72.8K
- Earning Date
- AEON 11-12-2025
- KZIA 12-26-2025
- Dividend Yield
- AEON N/A
- KZIA N/A
- EPS Growth
- AEON N/A
- KZIA N/A
- EPS
- AEON N/A
- KZIA N/A
- Revenue
- AEON N/A
- KZIA $1,246,312.00
- Revenue This Year
- AEON N/A
- KZIA N/A
- Revenue Next Year
- AEON N/A
- KZIA N/A
- P/E Ratio
- AEON N/A
- KZIA N/A
- Revenue Growth
- AEON N/A
- KZIA N/A
- 52 Week Low
- AEON $0.38
- KZIA $2.86
- 52 Week High
- AEON $64.80
- KZIA $34.40
- Technical
- Relative Strength Index (RSI)
- AEON 48.00
- KZIA 54.09
- Support Level
- AEON $0.89
- KZIA $7.18
- Resistance Level
- AEON $1.09
- KZIA $7.99
- Average True Range (ATR)
- AEON 0.07
- KZIA 0.46
- MACD
- AEON -0.01
- KZIA 0.03
- Stochastic Oscillator
- AEON 31.38
- KZIA 72.19
About AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.